Cystic fibrosis survival outcomes following second lung transplant: The north American experience

Author:

Alshehri Moayad12,Ramos Kathleen J.3,Sykes Jenna1,Ma Xiayi1,Stanojevic Sanja4,Quon Bradley S.5,Marshall Bruce C.6,Cromwell Elizabeth6ORCID,Ostrenga Joshua S.6,Faro Albert6,Elbert Alexander6,Todd Jonathan6,Chaparro Cecilia7,Goss Christopher H.38,Stephenson Anne L.1910

Affiliation:

1. Department of Respirology St. Michael's Hospital Toronto Ontario Canada

2. Unit of Pulmonology Internal Medicine Department King Saud University Riyadh Saudi Arabia

3. Division of Pulmonary Critical Care and Sleep Medicine Department of Medicine University of Washington Medical Center Seattle Washington USA

4. Department of Community Health and Epidemiology Dalhousie University Halifax Nova Scotia Canada

5. Centre for Heart Lung Innovation Department of Medicine University of British Columbia Vancouver British Columbia Canada

6. Cystic Fibrosis Foundation Bethesda Maryland USA

7. Toronto Lung Transplant Program University Health Network Toronto Canada

8. Division of Pediatric Pulmonary Department of Pediatrics University of Washington Medical Center Seattle Washington USA

9. Keenan Research Centre Li Ka Shing Knowledge Institute of St Michael's Hospital Toronto Ontario Canada

10. Institute of Health Policy Management and Evaluation University of Toronto Toronto Ontario Canada

Abstract

AbstractIntroductionRe‐transplant is an option for those who develop end‐stage lung disease due to rejection; however, little data exist following re‐transplantation in cystic fibrosis (CF).MethodsData from the Canadian CF Registry and US CF Foundation Patient Registry supplemented with data from United Network for Organ Sharing were used. Individuals who underwent a 2nd lung transplant between 2005 and 2019 were included. The Kaplan‐Meier method was used to estimate the probability of survival post‐second transplant at 1, 3, and 5‐years.ResultsOf those people who were waitlisted for a second transplant (N = 818), a total of 254 (31%) died waiting, 395 (48%) were transplanted and 169 (21%) people were alive on the waitlist. Median survival time after 2nd lung transplant was 3.3 years (95% CI: 2.8‐4.1). The 1‐, 3‐ and 5‐year survival rates were 77.4% (95% CI: 73.1‐82%), 52% (95% CI: 46.7‐58%) and 39.4% (95% CI: 34.1‐45.6%).ConclusionsSurvival following second lung transplant in CF patients is lower than estimates following the first transplant. Over half of subjects who are potentially eligible for a second transplant die without receiving a second organ. This warrants further investigation.

Funder

Cystic Fibrosis Foundation Therapeutics

Publisher

Wiley

Subject

Transplantation

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3